This is a substantive revision of the bill, primarily expanding its scope to include 'medical clearance' in addition to 'medical certification' and clarifying the information to be provided to aviation stakeholders. v2 also adds new consultation requirements, specifies additional content for the medication list, and introduces a savings clause to limit the Administrator's liability.
Aviation Medication Transparency Act of 2026
- Sponsor
- Sen. Duckworth, Tammy [D-IL]
- Committees
- Commerce, Science, and Transportation Committee (primary)
- Last action
- Sep 14, 2026
Bottom line
This bill aims to increase transparency and accessibility of FAA medication policies for aviation professionals, potentially streamlining medical certification and enhancing safety through clearer guidance.
What it actually does
This bill mandates that the Administrator of the Federal Aviation Administration (FAA) publish and maintain a publicly available, user-friendly list of medications that are approved or prohibited for airmen and air traffic control specialists seeking medical certification or clearance. It requires extensive consultation with various aviation stakeholders during the list's development and specifies detailed content requirements, including contra-indications and stabilization periods. The bill also includes a savings clause to limit FAA liability.
Proponents argue
Proponents argue that the current system for medication guidance is often opaque and difficult for airmen and air traffic control specialists to navigate, leading to confusion, delays, and potential safety risks. By providing a clear, publicly accessible, and regularly updated list, this bill will empower aviation professionals to make informed decisions about their health and medication use, reducing uncertainty and fostering a safer aviation environment. The mandated consultation with industry experts ensures the list is practical and addresses real-world concerns.
Opponents contend
Critics might contend that while transparency is valuable, codifying such a detailed list could introduce rigidity into FAA medical policy, potentially hindering the agency's ability to adapt quickly to new medical research or emerging medications without legislative intervention. Concerns could also be raised regarding the administrative burden and cost of developing and maintaining such a comprehensive and frequently updated public database, potentially diverting resources from other critical safety functions. Some may also argue that the FAA's existing 'Guide for Aviation Medical Examiners' already serves this purpose, and a separate public list might create redundancy or inconsistencies.
The bill is concise and clearly written, making it accessible for a quick read and easy comprehension of its core purpose and requirements.
Section 2(b)
Requirement to Publish and Maintain a Public Medication List
This section mandates that the FAA Administrator must, within one year of the bill's enactment, publish and continuously update a list on a publicly available FAA website. This list will detail medications that the Administrator has determined are safe for airmen and air traffic control specialists to use for medical certification or clearance purposes, including both prescription and over-the-counter drugs.
Supporters argue
Supporters contend that a centralized, publicly available list will significantly reduce confusion and administrative burden for aviation professionals, allowing them to proactively manage their health and medication use in compliance with FAA regulations. This transparency is crucial for maintaining a healthy and compliant workforce.
Critics contend
Some might argue that while transparency is generally beneficial, the FAA's existing 'Guide for Aviation Medical Examiners' already provides this information, and creating a separate, potentially redundant, public list could lead to inconsistencies or additional administrative overhead without a significant improvement in utility.
Tradeoffs
This provision balances the desire for public transparency and ease of access for individuals against the potential for administrative burden and the need to ensure consistency with existing, more detailed guidance for medical examiners.
Section 2(c)
Specifics for List Content, Accessibility, and Stakeholder Consultation
This section outlines detailed requirements for the medication list. It must include 'Do Not Issue' or 'Do Not Fly' medications, allowed medications (prescription and OTC), contra-indications, and whether FAA review is needed. It also requires the list to be drafted in a user-friendly and accessible manner, made available via MedXPress, and include contact information for medical providers. Crucially, the FAA must consult with a wide range of stakeholders, including the Aeromedical Innovation and Modernization Working Group, pilot and air traffic controller unions, aviation schools, and general aviation organizations, before disseminating the list.
Section 2(d) and 2(e)
Regular Updates and Limitation of Liability
Section 2(d) mandates that the FAA update the medication list annually, and also whenever relevant information in the 'Guide for Aviation Medical Examiners' or other FAA medical certification policy is updated. Section 2(e) includes a savings clause, clarifying that the FAA is not liable if an individual relies on the list and experiences an adverse medical reaction, causes harm or injury, or is still deemed ineligible for a medical certification or medical clearance.
This section, titled 'Savings Clause,' explicitly states that the publication of the medication list does not assign liability to the FAA Administrator for any adverse medical reactions, harm, or ineligibility for medical certification that an individual experiences after relying on the list.
Section 2(e)
Why it matters:This is standard legislative practice to protect government agencies when they provide public information that individuals might rely on for personal decisions. It clarifies the limits of the agency's responsibility and ensures that providing transparency does not create undue legal risk for the FAA.
Case for: This clause protects the FAA from potential lawsuits arising from individuals misinterpreting or misapplying the information provided on the list. Without such protection, the agency might be hesitant to publish comprehensive guidance, thus hindering transparency efforts.
Case against: While standard, some might argue that this clause could be perceived as diminishing the FAA's accountability for the accuracy or clarity of the information it provides, potentially placing an excessive burden of interpretation and risk on the individual airman or air traffic control specialist.
Estimated impact: Prevents potential future litigation against the FAA related to the medication list, ensuring agency resources are not diverted to defending against such claims. It reinforces the principle of individual responsibility in medical decisions.